Spots Global Cancer Trial Database for Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
Official Title: An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Study ID: NCT00511238
Conditions
Study Description
Brief Summary: To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma. Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southern Cancer Center, Mobile, Alabama, United States
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Tower Cancer Research Foundation, Beverly Hills, California, United States
City of Hope National Medical Center, Duarte, California, United States
Scripps Clinic, La Jolla, California, United States
University of California, San Francisco, San Francisco, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Northwestern Universtiy, Chicago, Illinois, United States
Rush University Medical Center, Chicago, Illinois, United States
University of Kentucky, Lexington, Kentucky, United States
University of Michigan, Ann Arbor, Michigan, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
St. Vincent Catholic Medical Center, New York, New York, United States
Wake Forest University, Winston-Salem, North Carolina, United States
Gabrail Cancer Center, Canton, Ohio, United States
Oncology & Hematology Care, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Northwest Cancer Center, Houston, Texas, United States
University of Utah, Salt Lake City, Utah, United States
University of Calgary, Calgary, Alberta, Canada
University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada
Leukemia/BMT Program of BC, Vancouver, British Columbia, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
Royal Victoria Hospital, Montreal, Quebec, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
